Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enalaprilat→

Enalaprilat Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
76420-72-9
Molecular formula
C18H24N2O5
Molecular weight
348.4 g/mol
Drug class
Intravenous angiotensin-converting enzyme (ACE) inhibitoractive metabolite of enalapril
Mechanism of action
Inhibits ACE, reducing conversion of angiotensin I to angiotensin II and decreasing aldosterone secretion. This reduces vasoconstriction and sodium retention and lowers blood pressure.
Indications / reported uses
  • Treatment of hypertension when oral therapy is not practical or appropriate using the intravenous formulation; dosing and monitoring are product- and setting-specific

Sources: US DailyMed — Enalaprilat injection · NLM MeSH — Enalaprilat · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enalaprilat Environmental Risk Assessment (ERA) (the Enalaprilat ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.